COVID-19 Impact on Global Tumor-Specific Antigen Market Size, Status and Forecast 2020-2026

August 2020 | 92 pages | ID: CDABE87037B7EN
QYResearch

Abstracts

This report focuses on the global Tumor-Specific Antigen status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Tumor-Specific Antigen development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Agilent Technologies
• Creative Diagnostics
• Go Therapeutics
• Lee Biosolutions
• Bio-Rad
• Biomrieux
• Caris Life Sciences
• Roche
• Abcam
• Merck Group
• PerkinElmer
• OriGene Technologies

Market segment by Type, the product can be split into

• Coding Region
• Non-Coding Region

Market segment by Application, split into

• Drug Discovery and Development
• Diagnostics
• Clinical and Basic Research
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Tumor-Specific Antigen status, future forecast, growth opportunity, key market and key players.
• To present the Tumor-Specific Antigen development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Tumor-Specific Antigen are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Tumor-Specific Antigen Revenue
1.4 Market Analysis by Type
  1.4.1 Global Tumor-Specific Antigen Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Coding Region
  1.4.3 Non-Coding Region
1.5 Market by Application
  1.5.1 Global Tumor-Specific Antigen Market Share by Application: 2020 VS 2026
  1.5.2 Drug Discovery and Development
  1.5.3 Diagnostics
  1.5.4 Clinical and Basic Research
  1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Tumor-Specific Antigen Industry Impact
  1.6.1 How the Covid-19 is Affecting the Tumor-Specific Antigen Industry
    1.6.1.1 Tumor-Specific Antigen Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Tumor-Specific Antigen Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Tumor-Specific Antigen Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Tumor-Specific Antigen Market Perspective (2015-2026)
2.2 Tumor-Specific Antigen Growth Trends by Regions
  2.2.1 Tumor-Specific Antigen Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Tumor-Specific Antigen Historic Market Share by Regions (2015-2020)
  2.2.3 Tumor-Specific Antigen Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Tumor-Specific Antigen Market Growth Strategy
  2.3.6 Primary Interviews with Key Tumor-Specific Antigen Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Tumor-Specific Antigen Players by Market Size
  3.1.1 Global Top Tumor-Specific Antigen Players by Revenue (2015-2020)
  3.1.2 Global Tumor-Specific Antigen Revenue Market Share by Players (2015-2020)
  3.1.3 Global Tumor-Specific Antigen Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Tumor-Specific Antigen Market Concentration Ratio
  3.2.1 Global Tumor-Specific Antigen Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Tumor-Specific Antigen Revenue in 2019
3.3 Tumor-Specific Antigen Key Players Head office and Area Served
3.4 Key Players Tumor-Specific Antigen Product Solution and Service
3.5 Date of Enter into Tumor-Specific Antigen Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Tumor-Specific Antigen Historic Market Size by Type (2015-2020)
4.2 Global Tumor-Specific Antigen Forecasted Market Size by Type (2021-2026)

5 TUMOR-SPECIFIC ANTIGEN BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Tumor-Specific Antigen Market Size by Application (2015-2020)
5.2 Global Tumor-Specific Antigen Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Tumor-Specific Antigen Market Size (2015-2020)
6.2 Tumor-Specific Antigen Key Players in North America (2019-2020)
6.3 North America Tumor-Specific Antigen Market Size by Type (2015-2020)
6.4 North America Tumor-Specific Antigen Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Tumor-Specific Antigen Market Size (2015-2020)
7.2 Tumor-Specific Antigen Key Players in Europe (2019-2020)
7.3 Europe Tumor-Specific Antigen Market Size by Type (2015-2020)
7.4 Europe Tumor-Specific Antigen Market Size by Application (2015-2020)

8 CHINA

8.1 China Tumor-Specific Antigen Market Size (2015-2020)
8.2 Tumor-Specific Antigen Key Players in China (2019-2020)
8.3 China Tumor-Specific Antigen Market Size by Type (2015-2020)
8.4 China Tumor-Specific Antigen Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Tumor-Specific Antigen Market Size (2015-2020)
9.2 Tumor-Specific Antigen Key Players in Japan (2019-2020)
9.3 Japan Tumor-Specific Antigen Market Size by Type (2015-2020)
9.4 Japan Tumor-Specific Antigen Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Tumor-Specific Antigen Market Size (2015-2020)
10.2 Tumor-Specific Antigen Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Tumor-Specific Antigen Market Size by Type (2015-2020)
10.4 Southeast Asia Tumor-Specific Antigen Market Size by Application (2015-2020)

11 INDIA

11.1 India Tumor-Specific Antigen Market Size (2015-2020)
11.2 Tumor-Specific Antigen Key Players in India (2019-2020)
11.3 India Tumor-Specific Antigen Market Size by Type (2015-2020)
11.4 India Tumor-Specific Antigen Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Tumor-Specific Antigen Market Size (2015-2020)
12.2 Tumor-Specific Antigen Key Players in Central & South America (2019-2020)
12.3 Central & South America Tumor-Specific Antigen Market Size by Type (2015-2020)
12.4 Central & South America Tumor-Specific Antigen Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Agilent Technologies
  13.1.1 Agilent Technologies Company Details
  13.1.2 Agilent Technologies Business Overview and Its Total Revenue
  13.1.3 Agilent Technologies Tumor-Specific Antigen Introduction
  13.1.4 Agilent Technologies Revenue in Tumor-Specific Antigen Business (2015-2020))
  13.1.5 Agilent Technologies Recent Development
13.2 Creative Diagnostics
  13.2.1 Creative Diagnostics Company Details
  13.2.2 Creative Diagnostics Business Overview and Its Total Revenue
  13.2.3 Creative Diagnostics Tumor-Specific Antigen Introduction
  13.2.4 Creative Diagnostics Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.2.5 Creative Diagnostics Recent Development
13.3 Go Therapeutics
  13.3.1 Go Therapeutics Company Details
  13.3.2 Go Therapeutics Business Overview and Its Total Revenue
  13.3.3 Go Therapeutics Tumor-Specific Antigen Introduction
  13.3.4 Go Therapeutics Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.3.5 Go Therapeutics Recent Development
13.4 Lee Biosolutions
  13.4.1 Lee Biosolutions Company Details
  13.4.2 Lee Biosolutions Business Overview and Its Total Revenue
  13.4.3 Lee Biosolutions Tumor-Specific Antigen Introduction
  13.4.4 Lee Biosolutions Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.4.5 Lee Biosolutions Recent Development
13.5 Bio-Rad
  13.5.1 Bio-Rad Company Details
  13.5.2 Bio-Rad Business Overview and Its Total Revenue
  13.5.3 Bio-Rad Tumor-Specific Antigen Introduction
  13.5.4 Bio-Rad Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.5.5 Bio-Rad Recent Development
13.6 Biomrieux
  13.6.1 Biomrieux Company Details
  13.6.2 Biomrieux Business Overview and Its Total Revenue
  13.6.3 Biomrieux Tumor-Specific Antigen Introduction
  13.6.4 Biomrieux Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.6.5 Biomrieux Recent Development
13.7 Caris Life Sciences
  13.7.1 Caris Life Sciences Company Details
  13.7.2 Caris Life Sciences Business Overview and Its Total Revenue
  13.7.3 Caris Life Sciences Tumor-Specific Antigen Introduction
  13.7.4 Caris Life Sciences Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.7.5 Caris Life Sciences Recent Development
13.8 Roche
  13.8.1 Roche Company Details
  13.8.2 Roche Business Overview and Its Total Revenue
  13.8.3 Roche Tumor-Specific Antigen Introduction
  13.8.4 Roche Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.8.5 Roche Recent Development
13.9 Abcam
  13.9.1 Abcam Company Details
  13.9.2 Abcam Business Overview and Its Total Revenue
  13.9.3 Abcam Tumor-Specific Antigen Introduction
  13.9.4 Abcam Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.9.5 Abcam Recent Development
13.10 Merck Group
  13.10.1 Merck Group Company Details
  13.10.2 Merck Group Business Overview and Its Total Revenue
  13.10.3 Merck Group Tumor-Specific Antigen Introduction
  13.10.4 Merck Group Revenue in Tumor-Specific Antigen Business (2015-2020)
  13.10.5 Merck Group Recent Development
13.11 PerkinElmer
  10.11.1 PerkinElmer Company Details
  10.11.2 PerkinElmer Business Overview and Its Total Revenue
  10.11.3 PerkinElmer Tumor-Specific Antigen Introduction
  10.11.4 PerkinElmer Revenue in Tumor-Specific Antigen Business (2015-2020)
  10.11.5 PerkinElmer Recent Development
13.12 OriGene Technologies
  10.12.1 OriGene Technologies Company Details
  10.12.2 OriGene Technologies Business Overview and Its Total Revenue
  10.12.3 OriGene Technologies Tumor-Specific Antigen Introduction
  10.12.4 OriGene Technologies Revenue in Tumor-Specific Antigen Business (2015-2020)
  10.12.5 OriGene Technologies Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Tumor-Specific Antigen Key Market Segments
Table 2. Key Players Covered: Ranking by Tumor-Specific Antigen Revenue
Table 3. Ranking of Global Top Tumor-Specific Antigen Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Tumor-Specific Antigen Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Coding Region
Table 6. Key Players of Non-Coding Region
Table 7. COVID-19 Impact Global Market: (Four Tumor-Specific Antigen Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Tumor-Specific Antigen Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Tumor-Specific Antigen Players to Combat Covid-19 Impact
Table 12. Global Tumor-Specific Antigen Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Tumor-Specific Antigen Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Tumor-Specific Antigen Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Tumor-Specific Antigen Market Share by Regions (2015-2020)
Table 16. Global Tumor-Specific Antigen Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Tumor-Specific Antigen Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Tumor-Specific Antigen Market Growth Strategy
Table 22. Main Points Interviewed from Key Tumor-Specific Antigen Players
Table 23. Global Tumor-Specific Antigen Revenue by Players (2015-2020) (Million US$)
Table 24. Global Tumor-Specific Antigen Market Share by Players (2015-2020)
Table 25. Global Top Tumor-Specific Antigen Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor-Specific Antigen as of 2019)
Table 26. Global Tumor-Specific Antigen by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Tumor-Specific Antigen Product Solution and Service
Table 29. Date of Enter into Tumor-Specific Antigen Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 32. Global Tumor-Specific Antigen Market Size Share by Type (2015-2020)
Table 33. Global Tumor-Specific Antigen Revenue Market Share by Type (2021-2026)
Table 34. Global Tumor-Specific Antigen Market Size Share by Application (2015-2020)
Table 35. Global Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 36. Global Tumor-Specific Antigen Market Size Share by Application (2021-2026)
Table 37. North America Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 39. North America Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 40. North America Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 41. North America Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 42. North America Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 43. Europe Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 45. Europe Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 47. Europe Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 49. China Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 50. China Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 51. China Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 52. China Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 53. China Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 54. China Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 55. Japan Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 57. Japan Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 59. Japan Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 63. Southeast Asia Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 65. Southeast Asia Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 67. India Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 68. India Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 69. India Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 70. India Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 71. India Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 72. India Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Tumor-Specific Antigen Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Tumor-Specific Antigen Market Share (2019-2020)
Table 75. Central & South America Tumor-Specific Antigen Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Tumor-Specific Antigen Market Share by Type (2015-2020)
Table 77. Central & South America Tumor-Specific Antigen Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Tumor-Specific Antigen Market Share by Application (2015-2020)
Table 79. Agilent Technologies Company Details
Table 80. Agilent Technologies Business Overview
Table 81. Agilent Technologies Product
Table 82. Agilent Technologies Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 83. Agilent Technologies Recent Development
Table 84. Creative Diagnostics Company Details
Table 85. Creative Diagnostics Business Overview
Table 86. Creative Diagnostics Product
Table 87. Creative Diagnostics Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 88. Creative Diagnostics Recent Development
Table 89. Go Therapeutics Company Details
Table 90. Go Therapeutics Business Overview
Table 91. Go Therapeutics Product
Table 92. Go Therapeutics Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 93. Go Therapeutics Recent Development
Table 94. Lee Biosolutions Company Details
Table 95. Lee Biosolutions Business Overview
Table 96. Lee Biosolutions Product
Table 97. Lee Biosolutions Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 98. Lee Biosolutions Recent Development
Table 99. Bio-Rad Company Details
Table 100. Bio-Rad Business Overview
Table 101. Bio-Rad Product
Table 102. Bio-Rad Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 103. Bio-Rad Recent Development
Table 104. Biomrieux Company Details
Table 105. Biomrieux Business Overview
Table 106. Biomrieux Product
Table 107. Biomrieux Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 108. Biomrieux Recent Development
Table 109. Caris Life Sciences Company Details
Table 110. Caris Life Sciences Business Overview
Table 111. Caris Life Sciences Product
Table 112. Caris Life Sciences Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 113. Caris Life Sciences Recent Development
Table 114. Roche Business Overview
Table 115. Roche Product
Table 116. Roche Company Details
Table 117. Roche Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 118. Roche Recent Development
Table 119. Abcam Company Details
Table 120. Abcam Business Overview
Table 121. Abcam Product
Table 122. Abcam Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 123. Abcam Recent Development
Table 124. Merck Group Company Details
Table 125. Merck Group Business Overview
Table 126. Merck Group Product
Table 127. Merck Group Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 128. Merck Group Recent Development
Table 129. PerkinElmer Company Details
Table 130. PerkinElmer Business Overview
Table 131. PerkinElmer Product
Table 132. PerkinElmer Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 133. PerkinElmer Recent Development
Table 134. OriGene Technologies Company Details
Table 135. OriGene Technologies Business Overview
Table 136. OriGene Technologies Product
Table 137. OriGene Technologies Revenue in Tumor-Specific Antigen Business (2015-2020) (Million US$)
Table 138. OriGene Technologies Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Tumor-Specific Antigen Market Share by Type: 2020 VS 2026
Figure 2. Coding Region Features
Figure 3. Non-Coding Region Features
Figure 4. Global Tumor-Specific Antigen Market Share by Application: 2020 VS 2026
Figure 5. Drug Discovery and Development Case Studies
Figure 6. Diagnostics Case Studies
Figure 7. Clinical and Basic Research Case Studies
Figure 8. Others Case Studies
Figure 9. Tumor-Specific Antigen Report Years Considered
Figure 10. Global Tumor-Specific Antigen Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Tumor-Specific Antigen Market Share by Regions: 2020 VS 2026
Figure 12. Global Tumor-Specific Antigen Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Tumor-Specific Antigen Market Share by Players in 2019
Figure 15. Global Top Tumor-Specific Antigen Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor-Specific Antigen as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Tumor-Specific Antigen Revenue in 2019
Figure 17. North America Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Tumor-Specific Antigen Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Agilent Technologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Agilent Technologies Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 26. Creative Diagnostics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Creative Diagnostics Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 28. Go Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Go Therapeutics Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 30. Lee Biosolutions Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Lee Biosolutions Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 32. Bio-Rad Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Bio-Rad Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 34. Biomrieux Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Biomrieux Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 36. Caris Life Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Caris Life Sciences Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 38. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Roche Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 40. Abcam Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Abcam Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 42. Merck Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Merck Group Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 44. PerkinElmer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. PerkinElmer Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 46. OriGene Technologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. OriGene Technologies Revenue Growth Rate in Tumor-Specific Antigen Business (2015-2020)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed